Biovail Expands Co-Promotion Arrangement With Reliant Pharmaceuticals for Cardizem XL.

Business Editors, Health/Medical Writers

TORONTO--(BUSINESS WIRE)--Nov. 14, 2002

Biovail Corporation (NYSE:BVF)(TSX:BVF)

-- Well-established physician relationships strengthen launch of Cardizem(R) XL

-- Increased call frequency to target physicians can enhance market penetration

Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has entered into a three-year agreement with privately held New Jersey-based Reliant Pharmaceuticals, LLC to provide 250 sales representatives beginning in January 2003 for the co-promotion of Biovail's new Cardizem(R) XL product, Teveten(R), Teveten(R) HCT and, on a seasonal basis, Cedax(R) and Rondec(R).

Reliant's sales force has extensive experience detailing cardiovascular products across the United States, has established strong relationships with high prescribing physicians and will be working in tandem with Biovail's existing sales force. This is an expansion of the previously disclosed relationship between Biovail and Reliant whereby Reliant is co-promoting Teveten(R) and other products with their sales representatives during the fourth quarter of 2002.

Cardizem(R) XL, which has received an Approvable Letter from the U.S. Food and Drug Administration (FDA), is a graded release formulation of diltiazem intended for evening dosing to provide better 24-hour control of diastolic and systolic blood pressure, in particular during the early morning rise in blood pressure. The addition of Cardizem(R) XL to Reliant's current portfolio of cardiovascular products allows for a well-focused cardiovascular-oriented sales call.

"This is an excellent opportunity for Biovail to enhance the launch of Cardizem(R) XL," said Eugene Melnyk, CEO and Chairman of Biovail Corporation. "The combination of both sales forces allows us to exceed our goal of having 800 representatives behind this product at launch. It also reduces the execution risk associated with the launch of a new therapy and allows Biovail to begin detailing physicians in January 2003 with an experienced cardiovascular sales force, immediately following the launch of the product to the trade later in the fourth quarter of 2002. With the support of Reliant's sales force, we anticipate an expansion in the frequency and number of physician calls that can be achieved, which should translate into greater market penetration for Cardizem(R) XL."

Reliant will be compensated by way of a tiered royalty on a portfolio of Biovail products that it will promote according to this agreement and therefore, Reliant's financial compensation is tied to the success of the promotion of these products. The companies will form a joint Promotion Committee to capitalize on the strengths of each company. In addition, Biovail will participate with some of Reliant's existing lenders in providing a term credit facility to Reliant.

"Reliant is extremely pleased to be working with Biovail on the co-promotion of these outstanding brands, as well as assisting Biovail with the launch of Cardizem(R) XL. The promotional synergies between our product portfolios offer a unique opportunity to maximize the value of Teveten(R) and Cardizem(R) XL, as well as that of our own growing cardiovascular franchise that includes Lescol(R) and Lescol(R) XL, for cholesterol management," said Joseph Krivulka, President of Reliant.

Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug delivery technologies.

Reliant is a rapidly growing, privately held company founded in 1999 to market branded, patent protected, ethical pharmaceutical products to primary care and targeted specialty physicians in the U.S. Reliant currently markets a portfolio of branded products, including: Lescol(R) (fluvastatin sodium) and Lescol(R) XL, (fluvastatin sodium extended release tablets), developed by Novartis for cholesterol management; DynaCirc(R) (isradipine) and DynaCirc CR(R) (isradipine an extended release tablets) formulation, also developed by Novartis for the treatment of hypertension; and Axid(R) (nizatidine) developed by Eli Lilly for the treatment of GERD and peptic ulcers. Reliant also develops and implements sophisticated life cycle management strategies to extend marketing exclusivity or provide additional patent protection for its products.

For further information, please contact Ken Howling, Vice President Finance at 905-286-3000 or send inquiries to [e-mail].

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.